Erasca CLO Ebun Garner sells $1.3m in ERAS stock By Investing.com

Erasca CLO Ebun Garner sold 80,000 shares on Apr 1, 2026 for $1.312M (prices $16.11–$16.58) and exercised 80,000 options at $1.70 ($136k); Garner now directly owns 25,076 shares under a June 30, 2024 Rule 10b5-1 plan. The company reported a Q4 2025 net loss of $29.1M and a FY 2025 loss of $124.6M, secured worldwide rights to ERAS-0015 by expanding the Joyo Pharmatech license to China, Hong Kong and Macau, and agreed with Tango Therapeutics to test ERAS-0015 with a PRMT5 inhibitor. Stifel, H.C. Wainwright and Clear Street raised price targets to $20 (Stifel and Clear Street maintained Buy ratings), and clinical updates include two confirmed partial responses in RAS‑mutant patients.

Analysis

Expanding geographic and combination footprints materially changes the commercialization and regulatory pathway rather than simply enlarging the TAM. China-facing regulatory review and local pricing dynamics typically add 12–36 months of timeline uncertainty and often force additional on-the-ground spend or local manufacturing commitments; investors should model an incremental cash burn and milestone- or royalty-driven revenue mix rather than immediate sales leverage.

The combination strategy with a PRMT5-targeted partner creates optionality: a positive synergistic signal can de-risk single-agent dependence and re-price the franchise, but negative or ambiguous combo data tends to compress value much faster than single-agent wins expand it. Competitors working on RAS or methyltransferase axes will respond by accelerating their own combo programs, raising the bar for demonstrable incremental benefit (e.g., durability or response rate lift) required to sustain premium multiples.

Near-term reversal risks are binary clinical readouts and financing cadence; absent a clean efficacy/safety signal or committed non-dilutive capital, upside from improved sentiment is vulnerable to being wiped out by a single negative cohort outcome or a down-round. Over a 3–12 month horizon, catalysts to watch are blinded progression data and any China regulatory interactions — over 12–24 months, watch cash runway, partnering tranche milestones, and enrollment velocity in combo cohorts.

The market currently prices optionality; that creates a trade-off for portfolios between limited-cost asymmetric upside and outright equity exposure ahead of de-risking events. A disciplined approach is to buy convexity with capped downside or to express exposure to the combo partner separately, rather than use concentrated outright long exposure that leaves investors exposed to dilution and binary clinical swings.

Key Decisions for Investors

• Buy ERAS Jan 2027 15/25 call spread (debit spread) sized to 1–2% of portfolio: limited max loss = premium, upside capped if clinical/combo progress re-rates the story over 6–18 months; target 2.5x return if catalyst-driven re-rating occurs.
• Initiate a tactical long position in TNGX (or the PRMT5-focused combo counter) sized 0.5–1% of portfolio to capture asymmetric upside from positive combo signals; pair with ERAS call spread to avoid single-asset binary risk.
• Pair trade: long ERAS equity (smaller position) / short XBI (size to sector beta) for 3–12 months to isolate company-specific upside while hedging broad biotech drawdowns; reevaluate post any major readout or financing.
• Sell ERAS 2026 12 puts for investors willing to be long at a lower basis: collect premium and set an effective acquisition price with downside defined by strike; cap position size to potential dilution scenarios and have cash ready for assignment.